Second Amendment to Release AgreementSecond Amendment to Release Agreement • September 6th, 2022 • Tyme Technologies, Inc. • Pharmaceutical preparations
This Amendment (the “Second Amendment”), effective as of September 2, 2022, is entered into by and between Tyme Technologies, Inc., a Delaware corporation (the “Company”), and Michael Demurjian (the “Stockholder”).
Company Letterhead]Separation and General Release Agreement • September 6th, 2022 • Tyme Technologies, Inc. • Pharmaceutical preparations • New Jersey
Under the terms of your April 28, 2022 retention letter agreement (your “April 2022 Retention Agreement”), you are eligible to receive a retention bonus when Tyme Technologies, Inc. (the “Company”) completes its merger (the “Merger”) with Syros Pharmaceuticals, Inc. (“Syros”). The Company is pleased to offer you additional benefits in exchange for providing assistance to the Company from today through the 90-day period following the date that it completes the Merger (the “Cooperation Period”), subject to the terms and conditions set forth in this letter agreement (the “Cooperation Agreement”).
